Endothelial dysfunction and multiorganomultivascular (polyorganopolyvascular) disease
Authors:
Peter Gavorník; Andrej Dukát; Ľudovít Gašpar; Martin Čaprnda; Alena Uhrinová; Kristína Letková; Naďa Hučková; Laura Gužiková; Katarína Böhmerová; Peter Sabaka; Jana Hodulíková; Gabriela Gubová; Alexandra Kunová; Mária Šulanová
Authors‘ workplace:
II. interná klinika, Prvé angiologické pracovisko, LF UK a Univerzitná nemocnica Bratislava
Published in:
Forum Diab 2012; 1(2-3): 77-85
Category:
Topic
Overview
Aim:
The aim of this Document of the Angiologists´ Section of the Slovak Medical Chamber (AS SMC, 2012) is to address a number of studies on endothelial dysfunction, arterial hypertension, metabolic syndrome and type 2 diabetes mellitus published in the last years in order to assess their contribution to our expanding knowledge of the multiorganomultivascular disease.
Discussion:
Angiometabolic syndrome X (AS SMC,1999) has been commonly defined by the presence of ten risk factors (hypersigns): hyperglycaemia (diabetes mellitus); hyperinsulinaemia (insulin resistance); hyperlipoproteinaemia (dyslipidaemia) – Non-Alcoholic Fatty Liver Disease (NAFLD); hyperweight (abdominal obesity) – risk of several cancer types; hypertension (arterial hypertension); hyperuricaemia and/or hyperhomocysteinaemia and/or hyperinflammation – nonvalvular atrial fibrillation; hyperhaemocoagulation (trombophilia); hyperviskosity; hyperactivity sympathetic nervous system and RAAS; hyperandrogenisms and hirsutism; and constitutes one of the most important medical issuess at present. Key etiopatogenetic mechanism of metabolic syndrome has been congenital, primary and secondary endothelial dysfunction that openes and closes the multiple vascular vicious circle (multicirculus vitiosus vasorum). The management of metabolic syndrome X and a significant change in its prevalence and incidence will be of importance in the coming decades in all medical systems of industrialised countries all over the world.
Conclusion:
Angiometabolic syndrome X is cause and consequence of functional (endothelial dysfunction) and of structural vascular injury. Vessels are culprits, implements and victims of arterial hypertension, angiometabolic syndrome X, type 2 diabetes mellitus and of multiorganomultivascular arterial disease.
Key words:
endothelial dysfunction – arterial hypertension – 2 type diabetes mellitus -vessels – multiorganomultivascular arterial disease – circulus vitiosus vasorum
Sources
1. ADVANCE Collaborative group. Intensive Blood Glucose Control and Vascular Outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560–2572.
2. Alberti KG, Zimmet PR. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Diabet Med 1998; 15(7): 539–553.
3. Alberti KGMM, Eckel RH, Grundy SC et al. Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society and International Association for the Study of obesity. Circulation 2009; 120(16): 1640–1645.
4. Celermajer DS, Sorensen KE, Bull C et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340(8828): 1111–1115.
5. Cines DB, Pollak ES, Buck CA et al. Endothelial Cells in Physiology and in the Pathophysiology of Vascular Disorders. Blood 1998; 91(10): 3527–3561.
6. Cooper-DeHoff RM, Gong Y, Handberg EM et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. INVEST study. JAMA 2010; 304(1): 61–68.
7. Corrado E, Rizzo M, Coppola G et al. An Update on the Role of Markers of Inflammation in Atherosclerosis. J Atheroscler Thromb 2010; 17(1): 1–11.
8. Čaprnda M, Dukát A, Lietava J, Fodor GJ. Metabolický syndróm a jeho asociácia s kardiovaskulárnymi ochoreniami na Slovensku. Cor et Vasa 2004; 46(1): 12–13.
9. Das UN. Is type 2 diabetes mellitus a disorder of the brain? Nutrition 2002; 18(7–8): 667–672.
10. Davignon J, Ganz P. Role of Endothelial Dysfunction in Atherosclerosis. Circulation 2004; 109 (Suppl III): III 27-III 32.
11. Dessapt C, Karraliedde J, Hernandez-Fuentes M et al. Circulating Vascular Progenitor Cells in Patients with Type 1 Diabetes and Microalbuminuria. Diabetes Care 2010; 33(4): 875–877.
12. Dukát A, Gavorník P, Kolesár J et al. Risk factors of ischaemic heart disease in population of 3 selected districts of Slovakia. Eur Heart J 1986; 7(Suppl A): 43–44.
13. Dukát A. Všeobecná angiológia (General Angiology). Prvý slovenský odborný lekársky časopis o cievnych chorobách a poruchách krvnej a lymfatickej cirkulácie. Interná med 2002; 2(3): 178.
14. Dukát A. Metabolický syndróm, obezita a hypertenzia. Interná med 2003; 3(6): 390–391.
15. Dukát A. Metabolický syndróm: svetlá a tiene. Curr Clin Pract 2006; 2(1): 4–8.
16. Einhorn D, Reaven GM, Cobin ER et al. American College of Endocrinology position statement of the insulin resistence syndrome. Endocr Pract 2003; 9(3): 237–252.
17. Filipová S. Manažment pacientov s vysokým kardiometabolickým rizikom. Čo je to kardiometabolické riziko a ako ho môžeme v klinickej praxi stanoviť? – 1. časť. Interná med 2007; 7(7–8): 374–377.
18. Filipová S. Manažment pacientov s vysokým kardiometabolickým rizikom. 2. časť – Dlhodobé liečebné ovplyvnenie pacientov s vysokým kardiometabolickým rizikom – súčasné trendy. Interná med 2007; 7(9): 439–443.
19. Foresta C, De Toni L, Ferlin A et al. Clinical Implication of endothelial progenitor cells. Expert Rev Mol Diagn 2010; 10(1): 89–105.
20. Föstermaun U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012; 33(7): 829–837.
21. Galajda P, Mokáň M, Prídavková D et al. Prevalencia metabolického syndrómu na Slovensku. Interná med 2007; 7(6): 325–331.
22. Gavorník P: Ateroskleróza a iné choroby tepien. Univerzita Komenského – vydavateľstvo UK. Bratislava 1999. ISBN 80–223–1422–6.
23. Gavorník P: Diabetic angiopathy – etiopathogenesis and clinical manifestation (hypersyndrome X). Brat Lek List 2000; 101(10): 569–576.
24. Gavorník P. Artériová hypertenzia – circulus vitiosus vasorum. Medikom/MediNews 2012; 2(2): 12–18.
25. Gavorník P, Galbavý Š. Clinical picture of arteriolosclerosis. Brat Lek List 2001; 102(7): 326–331.
26. Gavorník P. Všeobecná angiológia. Angiologická propedeutika. Cievne choroby. 2. rozšírené a doplnené vyd. Univerzita Komenského – vydavateľstvo UK. Bratislava: 2001. ISBN 80–223–1608–3.
27. Gavorník P, Dukát A, Krahulec B, Gašpar Ľ, Lietava J. Hypersyndróm X (syndróm desať). Všeob angiol 2002; 2(1): 22–25.
28. Gavorník P. Vaskulárna endotelová dysfunkcia – etiopatogenéza, základné diagnostické metódy a liečebné možnosti. Všeob angiol 2002; 2(2): 59–66.
29. Gavorník P. Hypersyndróm X (syndróm „iks“ alebo „desať“). Diabetik 2003; 1(1): 4–7.
30. Gavorník P, Dukát A, Gašpar Ľ. Metabolický syndrom X ako cievna porucha. Curr Clin Pract 2007; 3(1): 52–55.
31. Gavorník P, Dukát A, Gašpar Ľ et al. Metabolický syndróm X – cievna porucha (choroba). Prakt Flebol 2007; 16(1): 10–15.
32. Gavorník P. Končatinovocievne ischemické choroby. B 2.1.: 1–92. In: Gavorník, P, Hrubiško M, Roborilová E (Eds.). Diferenciálna diagnostika kardio-vaskulárnych, respiračných a hematologických ochorení. Bratislava: Dr. Josef Raabe 2010. ISBN 978–80–89182–46–6.
33. Gavorník P. Obliterujúce choroby artérií a končatinovocievna ischemická choroba. Nová klinicko-etiologicko-anatomicko-patofyziologická (CEAP) klasifikácia. Cardiology 2010; 19(3): 201–213.
34. Gavorník P. Etiopatogenéza neurovaskulárnych ischemických chorôb (syndrómov). Neurológia 2010; 5(2): 61–68.
35. Gavorník P. Nevyhnutnosť neustáleho prehodnocovania manažmentu artériovej hypertenzie ako cievnej choroby cievnych chorôb. Medikom/Medinews 2011; 1(2): 12–13.
36. Gavorník P. Aktuálne odporúčania pre manažment fibrilácie predsiení a jej systémových artériových tromboembolických komplikácií. Medikom/Medinews 2011; 1(3): 12–14.
37. Gavorník P, Dukát A, Gašpar Ľ et al. Prevencia a liečba orgánovocievnych artériových ischemických chorôb. Prakt Lék 2010; 90(12): 708–714.
38. Gemstein HC, Miller ME, Byington RP et al. Action To Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24): 2545–2559.
39. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. (Constituted by reepresentatives of nine societies and by invited experts). Eur Heart J 2007; 28(19): 2375–2414.
40. Grundy SM, Brewer HB, Cleeman JI et al. Report of the National Heart, Lung and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition: Definition of Metabolic Syndrome. Circulation 2004; 109(3): 433–438.
41. Hrnčiar J, Hrnčiarová M, Kaliská G, et al. Mikrovaskulárna angína pektoris ako súčasť syndrómu inzulínovej rezistencie. Interná med 2007; 7(6): 341–347.
42. Hrnčiar J. Nové pohľady na obezitu. Obezita ako dominantný fenomén v etiopatogenéze metabolického syndrómu. Interná med 2007; 7(9): 473–480.
43. Hrnčiar J, Hrnčiarová M, Okapcová J et al. Dilemy koncepcie metabolického syndrómu X pri 20-ročnom jubileu jej vzniku – 1. časť. Interná med 2008; 8(6): 339–344.
44. Hrnčiar J, Hrnčiarová M, Okapcová J et al. Terapeutické dilemy syndrómu inzulínovej rezistencie pri 20. výročí jeho vzniku – 2. časť. Interná med 2008; 8(6): 345–350.
45. Innis SM. Metabolic programming of long-term outcomes due to fatty acid nutrition in early life. Matern Child Nutr 2011; 7(Suppl 2): 112–123.
46. Ip JH, Fuster V, Badimon L et al. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J Amer Coll Cardiol 1990; 15(7): 1667–1687.
47. Kastorini Ch-M, Milionis HJ, Esposito K et al. The Effect of Mediteranean Diet on Metabolic syndrome and its components. A Meta-Analysis of 50 studies and 534,906 Individuals. J Am Coll Cardiol 2011; 57(11): 1299–1313.
48. Klimeš I, Šeboková E, Tkáč I. Metabolický syndróm. In: Kreze A (ed). Všeobecná a klinická endokrinológia. Bratislava: SAP 2004.
49. Kollár J. Perspektívy terapie endotelovými progenitorovými bunkami. Ateroskleróza 2010; 14(3–4): 13–32.
50. Krahulec B. Obezita a niektoré faktory prostredia podporujúce vznik metabolického syndrómu. Cardiol 2005; 14(4): 161–165.
51. Lamon BD, Hajjar DP. Inflammation at the Molecular Interface of Atherogenesis. An Antropological Journey. Am J Pathol 2008; 173(5): 1253–1264.
52. Mancia G, De Backer G, Dominiczak et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105–1187.
53. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27(11): 2121–2158.
54. Matsumura M, Fukuda N, Kobayashi N et al. Effects of Atorvastatin on Angiogenesis in hindlimb ischaemia and endothelial progenitor cell formation in Rats. J Atheroscl Thromb 2009; 16(4): 319–326.
55. Mestas J, Ley K. Monocyte-Endothelial Cell Interactions in the development of atherosclerosis. Trends Cardiovasc Med 2008; 18(6): 228–232.
56. Morel O, Toti F, Hugel B et al. Procoagulant microparticles: disrupting the vascular equation? Arterioscler Thromb Vasc Biol 2006; 26(12): 2594–2604.
57. Niboshi A, Hamaoka K, Sakata K et al. Endothelial dysfunction in adult patients with a history of Kawasaki disease. Europ J Pediatr 2008; 167(2): 189–196.
58. Osto E, Coppolino G, Volpe M et al. Restoring the Dysfunctional Endothelium. Curr Pharm Des 2007; 13(10):1053–1068.
59. Ota H, Eto M, Ogawa S et al. SIRT1/eNOS as a Potential Target against Vascular Senescence, Dysfunction and Atherosclerosis. J Atheroscler Thromb 2010; 17(5): 1–5.
60. Patel SD, Waltham M, Wadoodi A et al. The Role of endothelial cells and their progenitors in intimal hyperplasia. Ther Adv Cardiovasc Dis 2010; 4(2): 129–141.
61. Pearson TA, Mensah GA, Alexander RW et al. AHA/CDC Scientific Statement. Markers inflammation and cardiovascular disease: application to clinical and public health practice. Circulation 2003; 107(3): 499–511.
62. Pella D, Thomas N, Tomlinson B, et al. Prevention of coronary artery disease: the south Asian Paradox. Lancet 2003; 361(9376): 2179.
63. Pella D (ed). Metabolický syndróm. Kardiol prax 2011; 9(1): 4–33.
64. Perk J, De Backer G, Gohlke H et al. Joint ESC Guidelines. European Guidelines on cardiovascular disease prevention in clinical practice (Version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33(13): 1635–1701. Dostupný tiež z : (DOI): http//doi:10.1093/eurheartj/ehs092
65. Reaven GM. Banting lecture 1988: Role insulin resistance in human disease. Diabetes 1988; 37(12): 1595–1607.
66. Reiner Ž, Catapano AL, DeBecker G et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32(14): 1769–1818.
67. Robinson R. The fetal origins of adult disease. BMJ 2001; 322(7283): 375–376.
68. Rosipal Š. Dysmetabolický syndróm v pediatrii. Ateroskleróza 2010; 14(3–4): 33–41.
69. Rydén L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28(1): 81–136.
70. Singh RB, Pella D, Mechirova V et al. Can brain dysfunction be a predisposing factor for metabolic syndrome? Bio Med Pharmacother J 2004; 58(Suppl 1): S56-S68.
71. Smadja DM, Gaussen P, Mauge L et al. Circulating Endothelial Cells. Circulation 2009; 119(3): 374–381.
72. Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J 2011; 32(16): 1968–1976.
73. Tendera M, Aboyans V, Bartelink M-L et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32(22): 2851–2906. Dostupný tiež z WWW (DOI): http://doi: 10.1093/eurheartj/ehr 211
74. The ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med 2010; 362(17): 1575–1585.
75. Topaloglu S, Boyaci A, Ayaz S et al. Coagulation, fibrinolytic system activation and Endothelial dysfunction in patients with mitral stenosis and sinus rhytm. Angiology 2007; 58(1): 85–91.
76. The IDF consensus worldwide of the metabolic syndrome. Dostupný z WWW: http://www.idf.org/VAT BE-433.674.528: 2005: 1–7 nebo z WWW: http://www.idf.org/metabolic-syndrome.
77. Tkáč I. Ovplyvnenie krvného tlaku a glykemickej kompenzácie v prevencii makrovaskulárnych a mikrovaskulárnych komplikácií diabetu 2. typu. Interná med 2007; 7(7–8): 383–392.
78. Ungvari Z, Orosz Z, Rivera A et al. Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol 2007; 292(5): H2417-H2424.
79. Vallance PJT, Webb DJ (eds). Vascular Endothelium in Human Physiology and Pathophysiology. London: Harwood Academic Press 2000: 285. ISBN 90–5702–489–6.
80. VAS (Vascular Independent Research and Education European Organization). Dostupný z WWW: http://www.vas-int.org.
81. Weis N. Lipid apheresis and rheopheresis for treatment of peripheral arterial disease. Atherosclerosis 2009; Suppl 10(5): 62–69.
82. Windler E, Zyriax B-Ch, Bamberger Ch et al. Current Strategies and Recent Advances in the Therapy of Hypercholesterolemia. Atherosclerosis Supplements 2009; 10(5): 1–4.
83. Yamahara K, Itoh H. Potential use of endothelial progenitor cells for regeneration of the vasculature. Ther Adv Cardiovasc Dis 2009; 3(1): 17–27.
84. Yusuf S, Diener HC, Sacco RL, et al. PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359(12): 1225–1237.
85. Yusuf S, Teo KK, Pogue J et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547–1559.
86. Zernecke A, Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res 2010; 86(2): 192–201.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2012 Issue 2-3
Most read in this issue
- Endothelial dysfunction and multiorganomultivascular (polyorganopolyvascular) disease
- Glucose variability: a new parameter of diabetes compensation?
- Diabetic retinopathy 2: Treatment of diabetic retinopathy and diabetic macular oedema
- Continuous glucose concentration monitoring